Bias in emerging biomarkers for bipolar disorder

Psychological Medicine

Volumn 46, Issue 11, 2016, Pages 2287-2297

  Carvalho, A F ^a   Kohler C A ^a   Fernandes, B S ^b,c   Quevedo, J ^d,e   Miskowiak, K W ^f   Brunoni, A R ^g   Machado Vieira, R ^g,h   Maes, M ^b   Vieta, E ⁱ   Berk, M ^b,j  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^f Rigshospitalet   (Denmark)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Bias; biomarkers; bipolar disorder; meta analysis; psychiatry; review

Indexed keywords

BIOLOGICAL MARKER;

BIPOLAR DISORDER; HUMAN; META ANALYSIS; PUBLISHING; STATISTICS AND NUMERICAL DATA;

BIOMARKERS; BIPOLAR DISORDER; HUMANS; PUBLICATION BIAS;

EID: 84969835596     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291716000957     Document Type: Article

References (56)

1. APA (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Publishing: Arlington, VA.
2. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I (2015). Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. Lancet Neurology 14, 263-273.
3. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yucel M, Gama CS, Dodd S, Dean B, Magalhaes PV, Amminger P, McGorry P, Malhi GS (2011). Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews 35, 804-817.
4. Birmaher B, Gill MK, Axelson DA, Goldstein BI, Goldstein TR, Yu H, Liao F, Iyengar S, Diler RS, Strober M, Hower H, Yen S, Hunt J, Merranko JA, Ryan ND, Keller MB (2014). Longitudinal trajectories and associated baseline predictors in youths with bipolar spectrum disorders. American Journal of Psychiatry 171, 990-999.
5. Brown NC, Andreazza AC, Young LT (2014). An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Research 218, 61-68.
6. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafo MR (2013). Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 14, 365-376.
7. Cuijpers P, Smit F, Bohlmeijer E, Hollon SD, Andersson G (2010). Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. British Journal of Psychiatry 196, 173-178.
8. Cuthbert BN (2014). The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 13, 28-35.
9. Dargel AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M (2015). C-reactive protein alterations in bipolar disorder: A meta-analysis. Journal of Clinical Psychiatry 76, 142-150.
10. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M (2015). Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Molecular Psychiatry 20, 152-153.
11. Diniz BS, Sibille E, Ding Y, Tseng G, Aizenstein HJ, Lotrich F, Becker JT, Lopez OL, Lotze MT, Klunk WE, Reynolds CF, Butters MA (2015). Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Molecular Psychiatry 20, 594-601.
12. Dupont WD, Plummer Jr. WD (1990). Power and sample size calculations. A review and computer program. Controlled Clinical Trials 11, 116-128.
13. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634.
14. Fava GA (2014). Road to nowhere. World Psychiatry 13, 49-50.
15. Fava GA, Guidi J, Grandi S, Hasler G (2014). The missing link between clinical states and biomarkers in mental disorders. Psychotherapy and Psychosomatics 83, 136-141.
16. Fernandes BS, Gama CS, Cereser KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F (2011). Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research 45, 995-1004.
17. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, Nardin P, Goncalves CA (2015). Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Molecular Psychiatry 20, 1108-1119.
18. First MB (2014). Preserving the clinician-researcher interface in the age of RDoC: the continuing need for DSM-5/ICD-11 characterization of study populations. World Psychiatry 13, 53-54.
19. Flint J, Cuijpers P, Horder J, Koole SL, Munafo MR (2015). Is there an excess of significant findings in published studies of psychotherapy for depression? Psychological Medicine 45, 439-446.
20. Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA, Leboyer M, Berk M, Malhi GS, Lopez-Jaramillo C, Taylor VH, Dodd S, Frangou S, Hall GB, Fernandes BS, Kauer-Sant'Anna M, Yatham LN, Kapczinski F, Young LT (2013). Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry 47, 321-332.
21. Fusar-Poli P, Radua J, Frascarelli M, Mechelli A, Borgwardt S, Di Fabio F, Biondi M, Ioannidis JP, David SP (2014). Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Human Brain Mapping 35, 3052-3065.
22. Girshkin L, Matheson SL, Shepherd AM, Green MJ (2014). Morning cortisol levels in schizophrenia and bipolar disorder: A meta-analysis. Psychoneuroendocrinology 49, 187-206.
23. Goldstein BI, Young LT (2013). Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Current Psychiatry Reports 15, 425.
24. Higgins J, Green S (2013). Cochrane Handbook for systematic reviews of interventions, version 5. 0. 2 (updated September 2009). The Cochrane Collaboration, 2009 (http://www. cochrane-handbook. org/). Accessed 18 August 2014.
25. Higgins JP (2008). Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. International Journal of Epidemiology 37, 1158-1160.
26. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21, 1539-1558.
27. Higgins JP, Thompson SG, Spiegelhalter DJ (2009). A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society. Series A (Statistics in Society) 172, 137-159.
28. Huedo-Medina TB, Sánchez-Meca J, Marin-Martinez F, Botella J (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychological Methods 11, 193.
29. Insel TR, Landis SC (2013). Twenty-five years of progress: the view from NIMH and NINDS. Neuron 80, 561-567.
30. Ioannidis JP (2005). Why most published research findings are false. PLoS Medicine 2, e124.
31. Ioannidis JP (2013). Clarifications on the application and interpretation of the test for excess significance and its extensions. Journal of Mathematical Psychology 57, 184-187.
32. Ioannidis JP, Panagiotou OA (2011). Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. Journal of the American Medical Association 305, 2200-2210.
33. Ioannidis JP, Tarone R, McLaughlin JK (2011). The false-positive to false-negative ratio in epidemiologic studies. Epidemiology 22, 450-456.
34. Ioannidis JP, Trikalinos TA (2007). An exploratory test for an excess of significant findings. Clinical Trials (London, England) 4, 245-253.
35. Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, Flax J, Samuelsson M, Traskman-Bendz L, Brundin L (2013). Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology 38, 853-862.
36. Kapur S, Phillips AG, Insel TR (2012). Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Molecular Psychiatry 17, 1174-1179.
37. Lin PY (2009). State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: A meta-analytic study. Neuroscience Letters 466, 139-143.
38. Looney SW, el-Mallakh RS (1997). Meta-analysis of erythrocyte Na, K-ATPase activity in bipolar illness. Depression and Anxiety 5, 53-65.
39. McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M, Lavoie S, Pantelis C, Yung A, Wood S, Hickie I (2014). Biomarkers and clinical staging in psychiatry. World Psychiatry 13, 211-223.
40. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013). Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biological Psychiatry 74, 15-25.
41. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 62, 1006-1012.
42. Munkholm K, Brauner JV, Kessing LV, Vinberg M (2013). Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis. Journal of Psychiatric Research 47, 1119-1133.
43. Munkholm K, Vinberg M, Vedel Kessing L (2013). Cytokines in bipolar disorder: A systematic review and meta-analysis. Journal of Affective Disorders 144, 16-27.
44. Murck H, Laughren T, Lamers F, Picard R, Walther S, Goff D, Sainati S (2015). Taking personalized medicine seriously: biomarker approaches in phase IIb/III studies in major depression and schizophrenia. Innovations in Clinical Neuroscience 12, 26s-40s.
45. Parnas J (2014). The RDoC program: Psychiatry without psyche? World Psychiatry 13, 46-47.
46. Phillips ML, Chase HW, Sheline YI, Etkin A, Almeida JR, Deckersbach T, Trivedi MH (2015). Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. American Journal of Psychiatry 172, 124-138.
47. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML (2015). BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis. Journal of Affective Disorders 174, 432-440.
48. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E, Churchill GC, Geddes JR, Goodwin GM (2014). Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychological Medicine 44, 2409-2418.
49. Scola G, Andreazza AC (2014). Current state of biomarkers in bipolar disorder. Current Psychiatry Reports 16, 514.
50. Sistrom CL, Mergo PJ (2000). A simple method for obtaining original data from published graphs and plots. American Journal of Roentgenology 174, 1241-1244.
51. Teixeira AL, Barbosa IG, Machado-Vieira R, Rizzo LB, Wieck A, Bauer ME (2013). Novel biomarkers for bipolar disorder. Expert Opinion on Medical Diagnostics 7, 147-159.
52. Tsilidis KK, Papatheodorou SI, Evangelou E, Ioannidis JP (2012). Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. Journal of the National Cancer Institute 104, 1867-1878.
53. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP (2013). Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Internal Medicine 173, 664-671.
54. Vieta E (2014). The bipolar maze: A roadmap through translational psychopathology. Acta Psychiatrica Scandinavica 129, 323-327.
55. WHO (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization: Geneva.
56. Young SS, Bang H (2004). The file-drawer problem, revisited. Science 306, 1133-1134; author reply 1133-1134.